RT Journal Article SR Electronic T1 Cross-reactive antibodies after SARS-CoV-2 infection and vaccination JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2021.05.26.21256092 DO 10.1101/2021.05.26.21256092 A1 Marloes Grobben A1 Karlijn van der Straten A1 Philip J.M. Brouwer A1 Mitch Brinkkemper A1 Pauline Maisonnasse A1 Nathalie Dereuddre-Bosquet A1 Judith A. Burger A1 Meliawati Poniman A1 Melissa Oomen A1 Dirk Eggink A1 Tom P.L. Bijl A1 Hugo D.G. van Willigen A1 Elke Wynberg A1 Bas J. Verkaik A1 Orlane J.A. Figaroa A1 Peter J. de Vries A1 Tessel M. Boertien A1 Roger Le Grand A1 Menno D. de Jong A1 Maria Prins A1 Amy W. Chung A1 Godelieve J. de Bree A1 Rogier W. Sanders A1 Marit J. van Gils YR 2021 UL http://medrxiv.org/content/early/2021/06/02/2021.05.26.21256092.abstract AB Current SARS-CoV-2 vaccines are losing efficacy against emerging variants and may not protect against future novel coronavirus outbreaks, emphasizing the need for more broadly protective vaccines. To inform the development of a pan-coronavirus vaccine, we investigated the presence and specificity of cross-reactive antibodies against the spike (S) proteins of human coronaviruses (hCoV) after SARS-CoV-2 infection and vaccination. We found an 11 to 123-fold increase in antibodies binding to SARS-CoV and MERS-CoV as well as a 2 to 4-fold difference in antibodies binding to seasonal hCoVs in COVID-19 convalescent sera compared to pre-pandemic healthy donors, with the S2 subdomain of the S protein being the main target for cross-reactivity. In addition, we detected cross-reactive antibodies to all hCoV S proteins after SARS-CoV-2 S protein immunization in macaques, with higher responses for hCoV more closely related to SARS-CoV-2. These findings support the feasibility of and provide guidance for development of a pan-coronavirus vaccine.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialThis study is a cross-sectional observational study without intervention, it was not registered with a trial ID.Funding StatementThis work was supported by a Netherlands Organization for Scientific Research (NWO) Vici grant (to R.W.S.); by the Bill & Melinda Gates Foundation through the Collaboration for AIDS Vaccine Discovery (CAVD) grants OPP1111923, OPP1132237, and INV-002022 to R.W.S.; by Health Holland PPS-allowance LSHM20040 (to M.J.v.G.) and by ZonMw (to M.D.d.J.). M.J.v.G. is a recipient of an AMC Fellowship from Amsterdam UMC and a COVID-19 grant from the Amsterdam Institute for Infection and Immunity. R.W.S and M.J.v.G. are recipients of support from the University of Amsterdam Proof of Concept fund (contract no. 200421) as managed by Innovation Exchange Amsterdam (IXA). A.W.C is supported by an NHMRC career development fellowship. The funders had no role in study design, data collection, data analysis, data interpretation, or data reporting.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:For the convalescent COVID-19 sera, approval was granted by the ethical review board of the Amsterdam University Medical Centers, location AMC, the Netherlands (NL 73281.018.20) and for the healthy controls, anonymized leftover serum from routine diagnostics for which ethical approval was waived by the ethics committee of the National Institute of Public Health and the Environment was used. The study was performed in accordance with the guidelines for sharing of patient data of observational scientific research in emergency situations as issued by the Commission on Codes of Conduct of the Foundation Federation of Dutch Medical Scientific Societies (https://www.federa.org/federa-english).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData supporting the findings in this manuscript are available from the corresponding author upon request.